Lantheus (NASDAQ:LNTH) Posts Quarterly Earnings Results, Misses Expectations By $0.23 EPS

Lantheus (NASDAQ:LNTH) released its earnings results on Wednesday. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23), Zacks reports. The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Lantheus updated its FY 2025 guidance to 7.000-7.200 EPS.

Lantheus Price Performance

Shares of LNTH traded down $0.64 during mid-day trading on Thursday, reaching $92.61. The stock had a trading volume of 319,272 shares, compared to its average volume of 864,204. Lantheus has a 52-week low of $56.44 and a 52-week high of $126.89. The business’s fifty day moving average is $89.81 and its 200 day moving average is $96.78. The firm has a market cap of $6.44 billion, a price-to-earnings ratio of 15.42 and a beta of 0.44.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several analyst reports. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Truist Financial upped their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price objective on shares of Lantheus in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $132.86.

Insider Activity at Lantheus

In related news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.50% of the stock is currently owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.